-
Cara Therapeutics (CARA) Announces 5M Share Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
UPDATE: Janney Montgomery Scott Assumes Cara Therapeutics (CARA) at Buy
-
Cara Therapeutics Reports Second Quarter 2018 Financial Results
-
Cara Therapeutics Reports Second Quarter 2018 Financial Results
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.5M Share Common Offering at $19/Sh
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
-
Cara Therapeutics (CARA) Announces Proposed 4.5M Share Common Offering
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more...)
-
Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...)
-
UPDATE: Janney Montgomery Scott Upgrades Cara Therapeutics (CARA) to Buy
-
Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
-
Janney Montgomery Scott Downgrades Cara Therapeutics (CARA) to Neutral
-
Cara Therapeutics (CARA): Catalyst Before Quarter End - Janney
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cara Therapeutics (CARA) Prices 4.45M Shares at $18
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics (CARA): Raising PT On Positive PhII Results - Janney
-
Cara Therapeutics (CARA): 4 Clinical Catalysts in 4 Months - Janney
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
Cara Therapeutics (CARA) Announces $65M Common Stock Offeirng
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Cara Therapeutics Announces Proposed Offering of Common Stock
-
Notable Analyst Rating Changes 02/25: (KGC) (ED) (EOG) Upgraded; (PAAS) (VVUS) (BAS) Downgraded
-
Janney Starts Cara Therapeutics (CARA) at Buy
-
Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
-
Cara Therapeutics (CARA) IPO Opens Higher and Gains Momentum
-
Cara Therapeutics Announces Pricing of Initial Public Offering

